Sanofi's New Approvals: Sanofi has received approval from China's National Medical Products Administration for two medicines targeting rare hematologic diseases: Qfitlia for hemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura.
Innovative Treatments: Qfitlia is the first antithrombin-lowering therapy for routine prophylaxis in hemophilia patients, while Cablivi is the first targeted therapy using Nanobody technology for treating acquired/immune-mediated thrombotic thrombocytopenic purpura in adolescents and adults.
Expansion of Portfolio: These approvals enhance Sanofi's rare hematology portfolio in China, addressing significant unmet medical needs in chronic bleeding disorders and acute clotting emergencies.
Health News Source: For more health-related news, readers are directed to visit rttnews.com.
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 78.52 USD with a low forecast of 57.00 USD and a high forecast of 116.57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 78.52 USD with a low forecast of 57.00 USD and a high forecast of 116.57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 46.500
Low
57.00
Averages
78.52
High
116.57
Current: 46.500
Low
57.00
Averages
78.52
High
116.57
UBS
Matthew Weston
Buy
to
Neutral
downgrade
2026-01-16
Reason
UBS
Matthew Weston
Price Target
AI Analysis
2026-01-16
downgrade
Buy
to
Neutral
Reason
UBS analyst Matthew Weston downgraded Sanofi to Neutral from Buy with a price target of EUR 88, down from EUR 105. The firm says the company's "failure to address pipeline replacement power is too great a strategic risk." It also sees less buyback potential for Sanofi, with the company likely having to focus on acquisitions.
Deutsche Bank
Emmanuel Papadakis
Buy
downgrade
2026-01-16
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
2026-01-16
downgrade
Buy
Reason
Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Sanofi to EUR 105 from EUR 110 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SNY
Unlock Now
Barclays
Overweight -> Equal Weight
downgrade
2026-01-06
Reason
Barclays
Price Target
2026-01-06
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Sanofi to Equal Weight from Overweight.
HSBC
Rajesh Kumar
Buy
downgrade
2025-12-10
Reason
HSBC
Rajesh Kumar
Price Target
2025-12-10
downgrade
Buy
Reason
HSBC analyst Rajesh Kumar lowered the firm's price target on Sanofi to EUR 100 from EUR 102 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
